Not every bright sign is guidance.

This is not a story about error.

It is a story about certainty.

deaths per year

From a treatment everyone believed worked.

This is the story of how we believed — and how we were wrong.

Patients with frequent PVCs after MI had 2–5× higher mortality.

400,000+
MI survivors/year
~40%
with significant PVCs
160,000
at elevated risk

A massive clinical need. A clear target.

Antiarrhythmic drugs were developed, FDA approved,
and prescribed to ~200,000 patients per year.

No villain appears in this story.

Everyone acted on the best evidence available.

PREMISE 1

PVCs after MI predict sudden cardiac death

PREMISE 2

Antiarrhythmic drugs suppress PVCs

PREMISE 3

Suppressing PVCs should prevent sudden death

The chain was logical. The conclusion felt inevitable.

Finally, someone asked: "Does suppressing PVCs actually save lives?"

Design
Randomized, double-blind, placebo-controlled
Population
Post-MI patients with asymptomatic PVCs
Intervention
Encainide, flecainide, or moricizine vs placebo
Run-in
Only patients with ≥80% PVC suppression randomized
Primary endpoint
Death or cardiac arrest with resuscitation
Sample size
1,498 patients (encainide/flecainide arms)

Outcome tested: survival. Not assumed. Measured.

Data Safety Monitoring Board stops the trial early.

Outcome Drug (n=755) Placebo (n=743)
Arrhythmic deaths 33 9
All cardiac deaths 43 16
Total deaths 56 22
Death rate 7.4% 3.0%
Relative Risk of Death: 2.5
95% CI: 1.6 – 4.5 | p < 0.001

The drugs that perfectly suppressed arrhythmias increased mortality by 150%.

Outcome
Drug
Placebo
RR (95% CI)
Arrhythmic death
33/755
9/743
3.6 (1.7-7.5)
Cardiac death
43/755
16/743
2.6 (1.5-4.7)
Total mortality
56/755
22/743
2.5 (1.5-4.0)
Overall
56/755
22/743
2.5 (1.5-4.0)
Favors Drug Favors Placebo

Every endpoint shows harm. The entire confidence interval excludes benefit.

Note: Forest plot shows outcomes within CAST, not pooled trials. I² = 0% (consistent harm).

The Human Cost

Before CAST, ~200,000 Americans per year received these drugs.

≈ 9,000

excess deaths per year — possibly more

Vietnam War: ~6,000 US deaths/year • These drugs: ~9,000+ deaths/year

For every number, a name we will never know.

Look again.

PREMISE 1

PVCs after MI predict sudden cardiac death

PREMISE 2

Antiarrhythmic drugs suppress PVCs

← THE LEAP
PREMISE 3

Suppressing PVCs should prevent sudden death

The assumption that suppressing the marker would fix the outcome was never tested.

1

PVCs were a marker of damaged tissue, not a cause of death

2

The drugs had proarrhythmic effects — triggering deadlier rhythms

3

The surrogate improved while the outcome worsened — a dissociated surrogate

The surrogate did not lie. We asked it the wrong question.

1

Biological plausibility is not proof

A logical mechanism doesn't guarantee the expected effect.

2

Surrogate endpoints can mislead

Improving a biomarker doesn't prove improvement in outcomes.

3

Only randomized trials establish causation

Observational data cannot prove intervention effects.

4

Consensus is not evidence

200,000 prescriptions, FDA approval, and guidelines were all wrong.

This is why we do meta-analysis: to see past apparent truths.

What appears certain may be wrong.

What everyone believes may be false.

Methods exist so patients do not pay for our confidence.

This is why you are here.

Not every bright sign is guidance.

Methods protect patients from our confidence.

← Course Library

Press arrow keys or click to navigate